Mallinckrodt

Global biopharmaceutical company Mallinckrodt plc announced results of a retrospective, observational medical chart review subgroup analysis assessing real-world treatment outcomes among African Americans with advanced symptomatic sarcoidosis who initiated therapy with Acthar Gel (repository corticotropin injection).

In recent months, the biotech and biopharma industries have been struggling with layoffs and dropping stocks. However, some companies are still experiencing success. Sanofi, AstraZeneca, Avillion and Diadem recently announced positive clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.

U.S. Capitol dome, Congress, Anerican flag

As the fairness of orphan drug exclusivities is debated in Congress, the U.S. Food and Drug Administration granted Orphan Drug designations to Editas Medicine and Neurocrine Biosciences.

Pfizer Inc. and the company’s partner BioNTech SE said on April 26 that they had submitted an application to the U.S. health regulator for the authorization of a booster dose of their COVID-19 vaccine for children aged 5 to 11 years.

AbbVie

AbbVie terminated the company’s collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement disorders.

A new study found that disulfiram, a drug used to treat chronic alcoholism, can safely reduce anxiety levels in rodents.

job cuts, layoffs

Magenta Therapeutics is reducing the company’s workforce by 14 percent in a revised operating plan to prioritize research and development.

The U.S. Food and Drug Administration placed a partial clinical hold on the TakeAim lymphoma study while the biotech company Curis provides further data to better understand safety and efficacy questions.

At the Clinical Trials Plenary Session at the 2022 AACR Annual Meeting, Dr. John Haanen, M.D., Ph.D., of the Netherlands Cancer Institute presented data from BioNTech’s ongoing first-in-human Phase I/II trial of the company’s CAR-T cell therapy BNT211 in patients with advanced solid tumors.

At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis receiving the investigational IL-13 inhibitor lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company announced April 11 at the 4th Annual Revolutionizing Atopic Dermatitis Conference.